Wikipedia -WSS

Wikipedia

author：focus 2025-10-01 00:52:32 - browse：1

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Does Paxlovid work in people vaccinated against Covid

entertainment

WSS

Nonprofit, backed by Microsoft, to certify AI tools in health care

STAT Virtual Event: JPM Recap, Live!

Hospital chaplains balance Covid safety with patients’ spiritual needs

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

JPM pitch from hospitals? Revenue streams outside of patient care

Study: Spinal cord stimulation helps patients with paralysis walk again

focus

Wikipedia

knowledge

Psychedelics group wrestles with new pharma identity

Can U.S. cancer drug shortages be fixed?

Supreme Court strikes down use of affirmative action

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Trump demands the U.S. pay no more for drugs than other countries … again

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Walensky prepares to leave CDC — and Congress — behind

Study suggests new cause of Down syndrome: cells linked to aging

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How the drug

leisure time

At JPM 2024, hospital systems pitch financial strength to investors

Meadows told special counsel he could not recall Trump ever declassifying Mar

Can U.S. cancer drug shortages be fixed?

Former Pear Therapeutics executives start new VC firm

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

American taxpayers paid $1.8 trillion in health care costs in 2022

entertainment

entertainment

knowledge

leisure time